Published in Hepatology on April 01, 2010
Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol (2010) 3.30
Pathobiology of liver fibrosis: a translational success story. Gut (2015) 1.72
Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med (2014) 1.64
Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey. Can J Gastroenterol Hepatol (2014) 1.37
Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol (2013) 1.33
Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. Liver Int (2012) 1.29
Validation of three coding algorithms to identify patients with end-stage liver disease in an administrative database. Pharmacoepidemiol Drug Saf (2012) 1.24
Role of magnetic resonance elastography in compensated and decompensated liver disease. J Hepatol (2013) 1.20
Invasive and non-invasive diagnosis of cirrhosis and portal hypertension. World J Gastroenterol (2014) 1.20
Non-invasive assessment of liver fibrosis. Ann Gastroenterol (2012) 1.07
Non invasive tools for the diagnosis of liver cirrhosis. World J Gastroenterol (2014) 1.00
Quantitative histological-hemodynamic correlations in cirrhosis. Hepatology (2012) 0.93
Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open (2016) 0.91
Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments. J Hepatol (2015) 0.90
The relationship between transient elastography and histological collagen proportionate area for assessing fibrosis in chronic viral hepatitis. J Gastroenterol (2012) 0.90
Cirrhosis and portal hypertension: The importance of risk stratification, the role of hepatic venous pressure gradient measurement. World J Hepatol (2015) 0.88
Pregnancy with portal hypertension. J Clin Exp Hepatol (2014) 0.88
Hepatic venous pressure gradient: clinical use in chronic liver disease. Clin Mol Hepatol (2014) 0.87
Acute-on-chronic liver failure: a review. Ther Clin Risk Manag (2014) 0.87
Ultrasonographic scoring system score versus liver stiffness measurement in prediction of cirrhosis. Clin Mol Hepatol (2013) 0.87
Varices and Variceal Hemorrhage in Cirrhosis: A New View of an Old Problem. Clin Gastroenterol Hepatol (2015) 0.86
Inflammatory status in human hepatic cirrhosis. World J Gastroenterol (2015) 0.86
Beyond a broken heart: circulatory dysfunction in the failing Fontan. Pediatr Cardiol (2014) 0.86
Transient elastography in Canada: Current state and future directions. Can J Gastroenterol Hepatol (2015) 0.85
A guide to the management of tuberculosis in patients with chronic liver disease. J Clin Exp Hepatol (2012) 0.85
Truncated active human matrix metalloproteinase-8 delivered by a chimeric adenovirus-hepatitis B virus vector ameliorates rat liver cirrhosis. PLoS One (2013) 0.84
Noninvasive methods for prediction of esophageal varices in pediatric patients with portal hypertension. World J Gastroenterol (2013) 0.83
Staging of liver fibrosis or cirrhosis: The role of hepatic venous pressure gradient measurement. World J Hepatol (2015) 0.82
Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis. PLoS One (2015) 0.81
Serum Sphingolipid Variations Associate with Hepatic Decompensation and Survival in Patients with Cirrhosis. PLoS One (2015) 0.81
The natural history of cirrhosis from parenteral nutrition-associated liver disease after resolution of cholestasis with parenteral fish oil therapy. Ann Surg (2015) 0.80
Clinical outcomes of compensated and decompensated cirrhosis: A long term study. World J Hepatol (2014) 0.80
A profile of volatile organic compounds in exhaled air as a potential non-invasive biomarker for liver cirrhosis. Sci Rep (2016) 0.79
Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy. Clin Infect Dis (2016) 0.78
Real-time two-dimensional shear wave ultrasound elastography of the liver is a reliable predictor of clinical outcomes and the presence of esophageal varices in patients with compensated liver cirrhosis. Croat Med J (2015) 0.77
A novel model to predict esophageal varices in patients with compensated cirrhosis using acoustic radiation force impulse elastography. PLoS One (2015) 0.77
Urinary metabolite profiling offers potential for differentiation of liver-kidney yin deficiency and dampness-heat internal smoldering syndromes in posthepatitis B cirrhosis patients. Evid Based Complement Alternat Med (2015) 0.77
Role of systemic inflammation in cirrhosis: From pathogenesis to prognosis. World J Hepatol (2015) 0.77
Association between Portal Vein Thrombosis and Survival in Non-Liver-Transplant Patients with Liver Cirrhosis: A Systematic Review of the Literature. Gastroenterol Res Pract (2015) 0.77
Reversibility of Stricturing Crohn's Disease-Fact or Fiction? Inflamm Bowel Dis (2016) 0.77
Portal hypertension in patients with cirrhosis: indirect assessment of hepatic venous pressure gradient by measuring azygos flow with 2D-cine phase-contrast magnetic resonance imaging. Eur Radiol (2015) 0.76
Histochemical Detection of Collagen Fibers by Sirius Red/Fast Green Is More Sensitive than van Gieson or Sirius Red Alone in Normal and Inflamed Rat Colon. PLoS One (2015) 0.76
Liver biopsy interpretation & the regression of hepatitis B virus related cirrhosis. Indian J Med Res (2014) 0.76
EUS-guided portal pressure gradient measurement with a simple novel device: a human pilot study. Gastrointest Endosc (2016) 0.76
Histological subclassification of cirrhosis. Hepatology (2010) 0.75
Biomarkers of bacterial translocation in advanced chronic liver disease: the key to individualizing prognosis. Ann Gastroenterol (2016) 0.75
Evaluating the risk of hepatocellular carcinoma in patients with prominently elevated liver stiffness measurements by FibroScan: a multicentre study. HPB (Oxford) (2016) 0.75
Portal hypertensive gastropathy as a prognostic index in patients with liver cirrhosis. BMC Gastroenterol (2016) 0.75
Quantitative Assessment of the Portal Pressure for the Liver Surgery Using Serological Tests. Ann Surg (2016) 0.75
Long-term change in incidence and risk factors of cirrhosis and hepatocellular carcinoma in Crete, Greece: a 25-year study. Ann Gastroenterol (2017) 0.75
Insulin-Like Growth Factor-1 Deficiency and Cirrhosis Establishment. J Clin Med Res (2017) 0.75
Evolving strategies for liver fibrosis staging: Non-invasive assessment. World J Gastroenterol (2017) 0.75
Risk of Rebleeding and Mortality in Cirrhotic Patients with Peptic Ulcer Bleeding: A 12-Year Nationwide Cohort Study. PLoS One (2017) 0.75
Recognizing and preventing death from compensated cirrhosis in the community. Liver Int (2011) 0.75
A new technique to improve the mechanical and biological performance of ultra high molecular weight polyethylene using a nylon coating. J Mech Behav Biomed Mater (2014) 0.75
Evaluation of liver fibrosis: "Something old, something new…". Ann Gastroenterol (2016) 0.75
Clinical Implications of the Serum Apelin Level on Portal Hypertension and Prognosis of Liver Cirrhosis. Gut Liver (2016) 0.75
A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats. Sci Rep (2017) 0.75
Use of non-selective beta blockers in cirrhosis: the evidence we need before closing (or not) the window. World J Gastroenterol (2015) 0.75
Variceal Hemorrhage in a Patient With Hepatitis C Virus Cirrhosis in Whom Liver Synthetic Function had Normalized After Viral Elimination. Hepatology (2016) 0.75
Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection. Pharmacoepidemiol Drug Saf (2017) 0.75
Clinical Application of Vibration Controlled Transient Elastography in Patients with Chronic Hepatitis B. J Clin Transl Hepatol (2017) 0.75
Liver stiffness predicts the response to direct-acting antiviral-based therapy against chronic hepatitis C in cirrhotic patients. Eur J Clin Microbiol Infect Dis (2016) 0.75
Histological grading and staging of chronic hepatitis. J Hepatol (1995) 19.57
Mechanisms of hepatic fibrogenesis. Gastroenterology (2008) 11.98
Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology (1982) 11.24
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet (1997) 10.05
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol (2002) 8.21
Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med (2005) 6.31
Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol (2005) 6.22
Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol (1995) 4.68
Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology (2007) 4.09
Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology (2007) 3.39
Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl (2006) 3.29
Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology (1990) 2.99
Reversal of hepatic fibrosis -- fact or fantasy? Hepatology (2006) 2.81
Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology (2009) 2.33
Angiogenesis in liver disease. J Hepatol (2008) 2.31
Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol (2009) 2.22
Prevention of variceal rebleeding. Lancet (2003) 2.16
The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization. J Clin Pathol (1978) 2.13
Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology (1998) 2.10
Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology (2006) 2.03
The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology (2006) 1.79
Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology (1999) 1.64
Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol (2004) 1.60
Elastography for the non-invasive assessment of liver disease: limitations and future developments. Gut (2009) 1.60
Angiogenesis in chronic inflammatory liver disease. Hepatology (2004) 1.57
Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis. J Hepatol (2005) 1.51
Vascular endothelial dysfunction in cirrhosis. J Hepatol (2007) 1.44
Transient elastography for diagnosis of portal hypertension in liver cirrhosis: is there still a role for hepatic venous pressure gradient measurement? Hepatology (2007) 1.06
Portal hypertension in chronic hepatitis: relationship to morphological changes. Gut (1990) 0.91
Correlation between liver morphology and portal pressure in alcoholic liver disease. Hepatology (1984) 0.90
Predictions from a hard liver. J Hepatol (2006) 0.86
Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology (2004) 6.14
Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology (2008) 5.77
Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology (2012) 3.86
Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85
Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol (2006) 3.59
Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology (2007) 3.39
Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution. Hepatology (2013) 3.06
Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis. Gastroenterology (2012) 2.83
Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango? Gut (2010) 2.70
Apoptosis: the nexus of liver injury and fibrosis. Hepatology (2004) 2.70
Angiogenesis in liver disease. J Hepatol (2008) 2.31
A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology (2007) 2.16
Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. Gut (2013) 2.10
StellaTUM: current consensus and discussion on pancreatic stellate cell research. Gut (2011) 2.07
gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis. Gut (2009) 2.06
Living and dying well with end-stage liver disease: time for palliative care? Hepatology (2012) 2.04
Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest (2003) 1.96
Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol (2009) 1.87
Sinusoidal remodeling and angiogenesis: a new function for the liver-specific pericyte? Hepatology (2007) 1.87
A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res (2005) 1.87
Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology (2003) 1.86
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. N Engl J Med (2015) 1.84
Scraping fibrosis: expressway to the core of fibrosis. Nat Med (2011) 1.82
Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology (2005) 1.81
Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology (2008) 1.71
Amelioration of hepatic fibrosis by NK cell activation. Gut (2010) 1.71
Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology (2008) 1.66
The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C. Gastroenterology (2003) 1.64
Beyond scoring: a modern interpretation of disease progression in chronic liver disease. Gut (2013) 1.63
Elastography for the non-invasive assessment of liver disease: limitations and future developments. Gut (2009) 1.60
Myofibroblast - like cells and liver fibrogenesis: Emerging concepts in a rapidly moving scenario. Mol Aspects Med (2007) 1.59
MARCKS actin-binding capacity mediates actin filament assembly during mitosis in human hepatic stellate cells. Am J Physiol Cell Physiol (2012) 1.58
Innate immunity in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol (2011) 1.55
Non invasive evaluation of portal hypertension using transient elastography. J Hepatol (2011) 1.42
Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology (2006) 1.38
Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol (2005) 1.33
Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. Am J Pathol (2007) 1.33
Transcriptional profiling reveals novel markers of liver fibrogenesis: gremlin and insulin-like growth factor-binding proteins. J Biol Chem (2006) 1.25
Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells. J Biol Chem (2004) 1.24
Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology (2005) 1.24
Prevention of severe toxic liver injury and oxidative stress in MCP-1-deficient mice. J Hepatol (2006) 1.24
Mechanisms of nitric oxide interplay with Rho GTPase family members in modulation of actin membrane dynamics in pericytes and fibroblasts. Am J Pathol (2005) 1.22
Non-invasive assessment of liver fibrosis: are we ready? Lancet (2010) 1.17
Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol (2006) 1.14
4-Hydroxynonenal as a selective pro-fibrogenic stimulus for activated human hepatic stellate cells. J Hepatol (2004) 1.14
Anti-fibrotic therapy: lost in translation? J Hepatol (2012) 1.12
Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J Hepatol (2009) 1.10
Antifibrogenic effects of canrenone, an antialdosteronic drug, on human hepatic stellate cells. Gastroenterology (2003) 1.07
Activation of p38(MAPK) mediates the angiostatic effect of the chemokine receptor CXCR3-B. Int J Biochem Cell Biol (2008) 1.07
Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans. J Hepatol (2002) 1.07
Adenosine monophosphate-activated protein kinase modulates the activated phenotype of hepatic stellate cells. Hepatology (2008) 1.06
A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis. Clin Gastroenterol Hepatol (2010) 1.05
Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis. World J Gastroenterol (2005) 1.04
Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Hepatol Int (2008) 1.04
Expression of transmembrane 4 superfamily (TM4SF) proteins and their role in hepatic stellate cell motility and wound healing migration. J Hepatol (2002) 1.04
Hyaluronic acid predicts hepatic fibrosis in children with nonalcoholic fatty liver disease. Transl Res (2010) 1.02
Hepatic wound repair. Fibrogenesis Tissue Repair (2009) 1.01
Increased risk of hepatocellular carcinoma and liver cirrhosis in vinyl chloride workers: synergistic effect of occupational exposure with alcohol intake. Environ Health Perspect (2004) 0.99
Twelve tips for teachers to encourage student engagement in academic medicine. Med Teach (2013) 0.98
Performance of Doppler ultrasound in the prediction of severe portal hypertension in hepatitis C virus-related chronic liver disease. Liver Int (2007) 0.98
Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol (2007) 0.98
Intracellular reactive oxygen species are required for directional migration of resident and bone marrow-derived hepatic pro-fibrogenic cells. J Hepatol (2010) 0.98
Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease. Liver Int (2012) 0.96
Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease. Ann Hepatol (2009) 0.96
The biphasic nature of hypoxia-induced directional migration of activated human hepatic stellate cells. J Pathol (2011) 0.95
Cell adhesion regulates platelet-derived growth factor-induced MAP kinase and PI-3 kinase activation in stellate cells. Hepatology (2002) 0.94
Developing strategies for liver fibrosis treatment. Expert Opin Investig Drugs (2002) 0.94
Myristoylated Alanine-Rich protein Kinase C Substrate (MARCKS) expression modulates the metastatic phenotype in human and murine colon carcinoma in vitro and in vivo. Cancer Lett (2013) 0.94
Non-invasive detection of pulmonary hypertension prior to renal transplantation is a predictor of increased risk for early graft dysfunction. Nephrol Dial Transplant (2010) 0.93
The metabolic syndrome and chronic liver disease. Curr Pharm Des (2014) 0.91
Curcumin limits the fibrogenic evolution of experimental steatohepatitis. Lab Invest (2009) 0.91
Reversal of liver fibrosis. Saudi J Gastroenterol (2009) 0.90
MARCKS is a downstream effector in platelet-derived growth factor-induced cell motility in activated human hepatic stellate cells. Exp Cell Res (2008) 0.90
Welcome to fibrogenesis & tissue repair. Fibrogenesis Tissue Repair (2008) 0.90
Evaluation of intracellular signalling pathways in response to insulin-like growth factor I in apoptotic-resistant activated human hepatic stellate cells. Fibrogenesis Tissue Repair (2009) 0.89
Role of the stromal-derived factor-1 (SDF-1)-CXCR4 axis in the interaction between hepatic stellate cells and cholangiocarcinoma. J Hepatol (2012) 0.89
Differential requirement of members of the MAPK family for CCL2 expression by hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol (2004) 0.88
Hepatic stellate cells stimulate HCC cell migration via laminin-5 production. Clin Sci (Lond) (2011) 0.88
An update on retinal circulation assessment technologies. Curr Eye Res (2003) 0.88
Lack of CC chemokine ligand 2 differentially affects inflammation and fibrosis according to the genetic background in a murine model of steatohepatitis. Clin Sci (Lond) (2012) 0.87
Mammalian target of rapamycin mediates the angiogenic effects of leptin in human hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol (2011) 0.86
Diagnostic power of fibroscan in predicting liver fibrosis in nonalcoholic fatty liver disease. Hepatology (2009) 0.85
Intrabiliary metastasis from rectal cancer mimicking peripheral papillary-type cholangiocarcinoma. J Hepatol (2004) 0.84
Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C. Dig Liver Dis (2013) 0.84
Neuron-derived orphan receptor 1 promotes proliferation of quiescent hepatocytes. Gastroenterology (2013) 0.82
Paediatric non-alcoholic fatty liver disease. Gut (2010) 0.81
Liver stiffness correlates with methotrexate cumulative dose in patients with rheumatoid arthritis. Dig Liver Dis (2011) 0.81
Nuclear localization of TRK-A in liver cells. Histol Histopathol (2008) 0.80
Curriculum design of a case-based knowledge translation shift for emergency medicine residents. Acad Emerg Med (2010) 0.78
A splice variant of ADAMTS13 is expressed in human hepatic stellate cells and cancerous tissues. Thromb Haemost (2010) 0.78
Liver stiffness, a non-invasive marker of liver disease: a core study group report. Antivir Ther (2010) 0.78
[Effects of alpha lipoic acid and pirfenidone on liver cells antioxidant modulation against oxidative damage]. Rev Med Chil (2014) 0.77
Increased expression of the oncogenic KLF6-SV1 transcript in human glioblastoma. Clin Chem Lab Med (2010) 0.77
Alcohol and global health: focus on acute pancreatitis needed. Lancet (2009) 0.77
Unraveling the spider web of hepatic stellate cell apoptosis. Gastroenterology (2009) 0.77
End-stage chronic liver disease: time to define a good death. Hepatology (2008) 0.76
Detection of a secreted metalloprotease within the nuclei of liver cells. Mol Biosyst (2011) 0.76